{
  "patent_number": "US 20160166668",
  "country": "US",
  "title": "How an mRNA Vaccine Targets Prostate Cancer with Six Antigens",
  "original_title": "Composition and vaccine for treating prostate cancer",
  "summary": "This patent describes an mRNA vaccine designed to treat prostate cancer by delivering genetic instructions for a specific combination of six prostate-related proteins, teaching the body to fight the cancer.",
  "what_it_does": "This patent describes a special mixture, called a composition, that contains at least one messenger RNA (mRNA) molecule. This mRNA carries the genetic blueprint for six specific proteins: STEAP, PSA, PSMA, PSCA, PAP, and MUC1 (Claim 1). These proteins are commonly found in prostate cancer cells. The goal is for the body's cells to read these mRNA instructions and produce these proteins, which then train the immune system to recognize and attack prostate cancer cells that also have these proteins (Abstract). The mRNA can be designed to carry instructions for all six proteins on a single strand (multicistronic) or have separate mRNA strands for each protein (Claim 1, 2, 3). For example, a patient could receive an injection of this mRNA composition, leading their immune system to develop a targeted defense against prostate cancer.",
  "what_it_does_not_cover": [
    "Does not cover an mRNA vaccine for prostate cancer that only includes some of the six specific antigens (STEAP, PSA, PSMA, PSCA, PAP, MUC1) but not all of them, as claimed in Claim 1.",
    "Does not cover an mRNA vaccine for prostate cancer that uses different prostate-specific antigens not explicitly listed in Claim 1.",
    "Does not cover non-mRNA vaccine approaches, such as traditional protein-based or viral vector vaccines, for treating prostate cancer.",
    "Does not cover mRNA vaccines designed to treat other types of cancer that do not involve these specific prostate antigens.",
    "Does not cover mRNA compositions that lack the specific stabilizing modifications described in claims 7-11, such as increased G/C content or specific 3' UTR elements like a poly(C) tail or histone stem-loop."
  ],
  "filed": "2016-02-19",
  "granted": null,
  "expires": "2036-02-19",
  "status": "active",
  "holder": "Curevac AG",
  "holder_url": "https://patentbrief.org/company/curevac-ag",
  "inventors": [
    {
      "name": "Thomas Lander",
      "url": "https://patentbrief.org/inventor/thomas-lander"
    },
    {
      "name": "Karl-Josef Kallen",
      "url": "https://patentbrief.org/inventor/karl-josef-kallen"
    },
    {
      "name": "Ulrike Gnad-Vogt",
      "url": "https://patentbrief.org/inventor/ulrike-gnad-vogt"
    },
    {
      "name": "Mariola Fotin-Mleczek",
      "url": "https://patentbrief.org/inventor/mariola-fotin-mleczek"
    }
  ],
  "times_cited": 84,
  "tags": [
    "biotech",
    "pharmaceutical",
    "oncology",
    "gene_editing"
  ],
  "abstract": "The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), STEAP (Six Transmembrane Epithelial Antigen of the Prostate), MUC1 (Mucin 1) and PAP (Prostatic acid phosphatase). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of prostate adenocarcinoma, locally limited, locally advanced, metastatic, castration-resistant (hormone-refractory), metastatic castration-resistant and non-metastatic castration-resistant prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and/or the vaccine.",
  "url": "https://patentbrief.org/patent/us/20160166668/composition-and-vaccine-for-treating-prostate-cancer",
  "markdown_url": "https://patentbrief.org/patent/us/20160166668/composition-and-vaccine-for-treating-prostate-cancer/md",
  "google_patents_url": "https://patents.google.com/patent/US20160166668",
  "relatedPatents": [
    {
      "patentNumber": "8278036",
      "countryCode": "US",
      "title": "How Modified RNA Tricks Cells Into Making Proteins Without Triggering Attacks",
      "url": "https://patentbrief.org/patent/us/8278036/rna-containing-modified-nucleosides-and-methods-of-use-thereof"
    },
    {
      "patentNumber": "10702600",
      "countryCode": "US",
      "title": "How Moderna's mRNA Vaccine Technology Targets Betacoronaviruses",
      "url": "https://patentbrief.org/patent/us/10702600/betacoronavirus-mrna-vaccine"
    },
    {
      "patentNumber": "9492534",
      "countryCode": "US",
      "title": "Using Genetically Modified Viruses to Target and Treat Cancer",
      "url": "https://patentbrief.org/patent/us/9492534/yescarta-axicabtagene-ciloleucel"
    },
    {
      "patentNumber": "10472419",
      "countryCode": "US",
      "title": "How Novartis Engineered Antibodies to Block the TIM-3 Immune Checkpoint",
      "url": "https://patentbrief.org/patent/us/10472419/keytruda-pembrolizumab"
    },
    {
      "patentNumber": "9845355",
      "countryCode": "US",
      "title": "How Genentech's Antibody Targets Cancerous B Cells",
      "url": "https://patentbrief.org/patent/us/9845355/tecentriq-atezolizumab"
    }
  ]
}